$30,000 of REVVITY INC. lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Diagnostic test reimbursement and policies Genomic sequencing T-Cell Immune Response Testing Proposals related to newborn screening Proposals related to pandemic preparedness FDA Medical Device Product policies H.R. 2810, Family Cord Blood Banking Act Medical Device & Pharmaceutical Adjacent Tariff"
You can find more data on corporate lobbying on Quiver Quantitative.
RVTY Congressional Stock Trading
Members of Congress have traded $RVTY stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $RVTY stock by members of Congress over the last 6 months:
- REPRESENTATIVE APRIL MCCLAIN DELANEY sold up to $50,000 on 02/28.
- REPRESENTATIVE ROBERT BRESNAHAN purchased up to $15,000 on 02/25.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
RVTY Insider Trading Activity
RVTY insiders have traded $RVTY stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $RVTY stock by insiders over the last 6 months:
- PRAHLAD R. SINGH (Please See Remarks) has made 0 purchases and 2 sales selling 18,365 shares for an estimated $2,134,365.
- JOEL S GOLDBERG (Please See Remarks) has made 0 purchases and 4 sales selling 15,170 shares for an estimated $1,922,512.
- TAJINDER S VOHRA (Please See Remarks) has made 0 purchases and 4 sales selling 5,492 shares for an estimated $641,542.
- MICHELLE MCMURRY-HEATH sold 1,970 shares for an estimated $235,395
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
RVTY Hedge Fund Activity
We have seen 242 institutional investors add shares of RVTY stock to their portfolio, and 221 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 2,969,326 shares (+16.7%) to their portfolio in Q4 2024, for an estimated $331,406,474
- SELECT EQUITY GROUP, L.P. removed 2,789,757 shares (-53.9%) from their portfolio in Q4 2024, for an estimated $311,364,778
- EDGEPOINT INVESTMENT GROUP INC. added 1,372,456 shares (+51.1%) to their portfolio in Q4 2024, for an estimated $153,179,814
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,151,821 shares (+17.8%) to their portfolio in Q4 2024, for an estimated $128,554,741
- ALLIANCEBERNSTEIN L.P. removed 850,921 shares (-86.6%) from their portfolio in Q4 2024, for an estimated $94,971,292
- JUNTO CAPITAL MANAGEMENT LP removed 487,202 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $54,376,615
- RGM CAPITAL, LLC added 339,733 shares (+34.6%) to their portfolio in Q4 2024, for an estimated $37,917,600
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
RVTY Analyst Ratings
Wall Street analysts have issued reports on $RVTY in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- KeyBanc issued a "Overweight" rating on 02/03/2025
- Barclays issued a "Overweight" rating on 02/03/2025
- Raymond James issued a "Outperform" rating on 01/21/2025
To track analyst ratings and price targets for RVTY, check out Quiver Quantitative's $RVTY forecast page.
RVTY Price Targets
Multiple analysts have issued price targets for $RVTY recently. We have seen 3 analysts offer price targets for $RVTY in the last 6 months, with a median target of $132.0.
Here are some recent targets:
- Andrew Cooper from Raymond James set a target price of $140.0 on 01/21/2025
- Eve Burstein from Bernstein set a target price of $130.0 on 01/10/2025
- Paul Knight from KeyBanc set a target price of $132.0 on 11/04/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
